心脉医疗: 心脉医疗：2025年半年度报告摘要

Core Viewpoint - Shanghai MicroPort Endovascular Medical Technology (Group) Co., Ltd. reported a significant decrease in revenue and net profit for the first half of 2025 compared to the same period in 2024, alongside a proposed cash dividend distribution to shareholders [1][4]. Financial Performance - Total revenue for the first half of 2025 was approximately 714.43 million yuan, a decrease of 9.24% compared to 787.17 million yuan in the same period of 2024 [4]. - Net profit attributable to shareholders was approximately 270.83 million yuan, down 29.96% from 386.65 million yuan year-on-year [4]. - The cash dividend proposed is 13.00 yuan per 10 shares, amounting to a total distribution of approximately 236.82 million yuan, which represents 75.26% of the net profit for the first half of 2025 [1]. Shareholder Information - As of July 31, 2025, the total number of shares was 123,262,117, with 2,178,271 shares held in a repurchase account [1]. - The largest shareholder, MicroPort Endovascular China Corp. Limited, holds 39.77% of the shares [5]. Asset Overview - Total assets at the end of the reporting period were approximately 4.60 billion yuan, reflecting a 7.29% increase from 4.29 billion yuan at the end of the previous year [2].